Edap Tms S.A. (NASDAQ:EDAP) has been given a $7.00 target price by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday. The firm currently has a “buy” rating on the medical equipment provider’s stock. HC Wainwright’s price target suggests a potential upside of 124.36% from the company’s previous close.

Several other research firms have also recently weighed in on EDAP. Zacks Investment Research upgraded shares of Edap Tms from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective for the company in a research report on Wednesday, June 7th. ValuEngine upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a research report on Friday, May 19th.

Shares of Edap Tms (NASDAQ:EDAP) traded down 4.00% during trading on Wednesday, hitting $3.12. The stock had a trading volume of 69,775 shares. Edap Tms has a 52 week low of $2.25 and a 52 week high of $3.85. The stock has a market capitalization of $90.47 million, a price-to-earnings ratio of 19.26 and a beta of 0.99. The stock’s 50 day moving average is $3.24 and its 200 day moving average is $2.96.

Edap Tms (NASDAQ:EDAP) last posted its quarterly earnings data on Wednesday, May 17th. The medical equipment provider reported $0.13 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.16. Edap Tms had a net margin of 11.95% and a return on equity of 27.90%. The firm had revenue of $9.29 million during the quarter, compared to analysts’ expectations of $9.35 million. On average, equities research analysts expect that Edap Tms will post $0.18 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “HC Wainwright Analysts Give Edap Tms S.A. (EDAP) a $7.00 Price Target” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/19/hc-wainwright-analysts-give-edap-tms-s-a-edap-a-7-00-price-target.html.

An institutional investor recently raised its position in Edap Tms stock. Perkins Capital Management Inc. raised its stake in shares of Edap Tms S.A. (NASDAQ:EDAP) by 184.3% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 276,500 shares of the medical equipment provider’s stock after buying an additional 179,250 shares during the period. Perkins Capital Management Inc. owned about 0.95% of Edap Tms worth $766,000 as of its most recent filing with the SEC. Institutional investors own 8.04% of the company’s stock.

Edap Tms Company Profile

EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.

Receive News & Ratings for Edap Tms S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms S.A. and related companies with MarketBeat.com's FREE daily email newsletter.